Making the Connection:
A Call to Action Against Undiagnosed Atrial Fibrillation

Curriculum Description

Atrial fibrillation (AF) affects an estimated 2.7 to 6.1 million people in the United States—a number that is expected to increase as the population ages. The majority of patients with AF have nonvalvular atrial fibrillation (NVAF), which is associated with increased morbidity and mortality and is a significant risk factor for stroke. Anticoagulation reduces the risk for stroke by about 70%, and the latest guidelines recommend that patients with AF and risk factors for stroke receive anticoagulation therapy indefinitely.

In this collection of PeerView activities, we offer a concise but high-level overview of essential research and clinical data focused on the detection and management of NVAF, including guideline recommendations for the use of approved direct oral anticoagulants (DOACs) and best practices for screening and diagnosis.

Target Audience

These activities have been designed to meet the educational needs of family medicine/general practice physicians, cardiologists, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other physicians that may recognize or manage atrial fibrillation.

Activities

1.0 CME
April 21, 2021

Weighing the Benefits and Risks of Treatment With DOACs in Individuals With NVAF or VTE

Sean Pokorney, MD, MBA

1.5 CME/MOC/NCPD/CPE
1:27:45
March 12, 2021

Adopting Telemedicine and Digital Tools for Atrial Fibrillation Management and Stroke Prevention

Khaldoun G. Tarakji, MD, MPH

1.0 CME
39:41
December 3, 2020

Improving Recognition to Reduce the Risk of Preventable Stroke

Sean Pokorney, MD, MBA

1.0 CME/CNE/CPE
35:43
March 27, 2020

Improving Detection and Reducing Risk

Christian T. Ruff, MD, MPH

0.5 CME/MOC/CNE/CPE
29:07
January 30, 2020

Real-World Evidence in Atrial Fibrillation

Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC

Coming Soon
0.5 CME/MOC/CNE/CPE
Coming Soon

Anticoagulation Therapy in NVAF: A Quality Improvement Initiative

Practice Aid Point-of-Care Tools

Weighing the Benefits and Risks of Treatment With DOACs in Individuals With NVAF or VTE

Adopting Telemedicine and Digital Tools for Atrial Fibrillation Management and Stroke Prevention

Improving Recognition to Reduce the Risk of Preventable Stroke

Improving Detection and Reducing Risk

Real-World Evidence in Atrial Fibrillation

Teaching & Learning Materials

Adopting Telemedicine and Digital Tools for Atrial Fibrillation Management and Stroke Prevention

Improving Recognition to Reduce the Risk of Preventable Stroke

Improving Detection and Reducing Risk

Real-World Evidence in Atrial Fibrillation

Additional Resources

Playlist

Adopting Telemedicine and Digital Tools for Atrial Fibrillation Management and Stroke Prevention

Khaldoun G. Tarakji, MD, MPH

Improving Recognition to Reduce the Risk of Preventable Stroke

Sean Pokorney, MD, MBA

Improving Detection and Reducing Risk

Christian T. Ruff, MD, MPH

Real-World Evidence in Atrial Fibrillation

Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC

Subscribe to Podcasts

Curriculum Collaborators & Support

This educational curriculum is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.